J. Boukovinas

535 total citations
12 papers, 445 citations indexed

About

J. Boukovinas is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, J. Boukovinas has authored 12 papers receiving a total of 445 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Epidemiology. Recurrent topics in J. Boukovinas's work include Lung Cancer Treatments and Mutations (6 papers), Cancer Treatment and Pharmacology (5 papers) and Neuroendocrine Tumor Research Advances (3 papers). J. Boukovinas is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer Treatment and Pharmacology (5 papers) and Neuroendocrine Tumor Research Advances (3 papers). J. Boukovinas collaborates with scholars based in Greece. J. Boukovinas's co-authors include George Fountzilas, Dimosthenis Skarlos, Meletios Α. Dimopoulos, P. Kosmidis, Epaminontas Samantas, C. Bacoyiannis, T. Economopoulos, D. Tsavdaridis, C. Nicolaides and Pavlos Papakostas and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

J. Boukovinas

11 papers receiving 425 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Boukovinas Greece	7	397	273	107	90	62	12	445
N. Vardakis Greece	11	348 0.9×	201 0.7×	113 1.1×	37 0.4×	68 1.1×	35	436
M. Lomas Spain	7	419 1.1×	364 1.3×	52 0.5×	39 0.4×	94 1.5×	23	518
Athina Agelidou Greece	14	629 1.6×	580 2.1×	78 0.7×	70 0.8×	146 2.4×	31	756
J.F. Seitz France	8	280 0.7×	154 0.6×	91 0.9×	46 0.5×	64 1.0×	29	365
M. Agelidou Greece	12	571 1.4×	430 1.6×	51 0.5×	166 1.8×	159 2.6×	26	661
Feiyu Niu China	12	266 0.7×	314 1.2×	130 1.2×	79 0.9×	175 2.8×	25	513
G. Pancera Italy	9	304 0.8×	164 0.6×	70 0.7×	51 0.6×	24 0.4×	19	395
Guoqiang Wang China	9	455 1.1×	227 0.8×	88 0.8×	34 0.4×	89 1.4×	24	561
Carol A. Sherman United States	13	317 0.8×	377 1.4×	56 0.5×	64 0.7×	125 2.0×	28	554
Longgang Cui China	7	297 0.7×	159 0.6×	72 0.7×	26 0.3×	61 1.0×	17	383

Countries citing papers authored by J. Boukovinas

Since Specialization

Citations

This map shows the geographic impact of J. Boukovinas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Boukovinas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Boukovinas more than expected).

Fields of papers citing papers by J. Boukovinas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Boukovinas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Boukovinas. The network helps show where J. Boukovinas may publish in the future.

Co-authorship network of co-authors of J. Boukovinas

This figure shows the co-authorship network connecting the top 25 collaborators of J. Boukovinas. A scholar is included among the top collaborators of J. Boukovinas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Boukovinas. J. Boukovinas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Kosmidis, P., George Fountzilas, Anastasia G Eleftheraki, et al.. (2010). Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). Annals of Oncology. 22(4). 827–834. 12 indexed citations

Kosmidis, P., George Fountzilas, Sofia Baka, et al.. (2008). Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A hellenic cooperative oncology group (HeCOG) phase II study.. PubMed. 27(6C). 4391–5. 7 indexed citations

Stathopoulos, G., K. Syrigos, Gerasimos Aravantinos, et al.. (2006). A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. British Journal of Cancer. 95(5). 587–592. 167 indexed citations

Ignatiadis, Michail, Dimitris Mavroudis, M. Veslemes, et al.. (2005). Sequential Versus Alternating Administration of Cisplatin/Etoposide and Topotecan as First-Line Treatment in Extensive-Stage Small-Cell Lung Cancer: Preliminary Results of a Phase III Trial of the Hellenic Oncology Research Group. Clinical Lung Cancer. 7(3). 183–189. 13 indexed citations

Androulakis, Nikolaos, J. Boukovinas, Sofia Agelaki, et al.. (2005). Docetaxel, cisplatin and gemcitabine as first line for patients with advanced/metastatic head and neck cancer. Journal of Clinical Oncology. 23(16_suppl). 5586–5586. 3 indexed citations

Stathopoulos, G., Gerasimos Aravantinos, K. Syrigos, et al.. (2005). A randomized phase III study of irinotecan/gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer. Journal of Clinical Oncology. 23(16_suppl). 4106–4106. 12 indexed citations

Agelaki, Sofia, J. Boukovinas, J. Varthalitis, et al.. (2004). A Multicenter Phase II Study of the Combination of Irinotecan and Gemcitabine in Previously Treated Patients with Small-Cell Lung Cancer. Oncology. 66(3). 192–196. 12 indexed citations

Potamianou, Anna, A. Polyzos, J. Boukovinas, et al.. (2004). Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as 1^st line treatment in patients with ovarian cancer: A multicenter phase II clinical trial. Journal of Clinical Oncology. 22(14_suppl). 5108–5108. 3 indexed citations

Polyzos, Aristidis, D. Mavroudis, J. Boukovinas, et al.. (2004). A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER-. Journal of Clinical Oncology. 22(14_suppl). 728–728. 3 indexed citations

10.

Polyzos, Aristidis, Dimitriοs Mavroudis, J. Boukovinas, et al.. (2004). A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER-. Journal of Clinical Oncology. 22(14_suppl). 728–728. 6 indexed citations

11.

Kosmidis, P., C. Nicolaides, Epaminontas Samantas, et al.. (2002). Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non–Small-Cell Lung Cancer: A Phase III Randomized Trial. Journal of Clinical Oncology. 20(17). 3578–3585. 206 indexed citations

12.

Kosmidis, P., N. Mylonakis, C. Nicolaides, et al.. (2001). Paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced NSCLC. Final results of a randomized phase III study. European Journal of Cancer. 37. S28–S29. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact